Described herein are haemolysis stabilising compositions and methods of use in the medical industry for the analysis of whole blood samples from patients. The compositions contain a combination of agents comprising at least one red blood cell membrane solubilisation agent, at least one chelating agent, at least one methaemoglobin binding agent, at least one pH buffering agent, at least one anticoagulant agent and at least one haemoglobin stabilising agent that contributes to improved stability of haemoglobin during transportation at ambient temperatures and improved ease of use in collecting and analysing the collected whole blood samples.